The neutralizing response to SARS-CoV-2 Omicron variants BA.1 and BA.2 in COVID-19 patients and homologous and heterologous vaccinees

Hum Vaccin Immunother. 2022 Nov 30;18(6):2129196. doi: 10.1080/21645515.2022.2129196. Epub 2022 Oct 21.

Abstract

The rapid replacement of Omicron BA.1 by BA.2 sublineage is very alarming, raising the question of whether BA.2 can escape the immunity acquired after BA.1 infection. We compared the neutralizing activity toward the Omicron BA.1 and BA.2 sub-lineages in five groups: COVID-19 patients; subjects who had received two doses of mRNA vaccine; subjects naturally infected with SARS-CoV-2 who had received two doses of mRNA; and subjects who had received three doses of homologous or heterologous vaccine. The results obtained highlight the importance of vaccine boosters in eliciting neutralizing antibody responses against Omicron sub-lineages, and suggest that the adenovirus vectored vaccine elicits a lower response against BA.1 than against BA.2 sub-lineage.

Keywords: Hybrid immunity; Omicron BA.1; Omicron BA.2; SARS-CoV-2; SARS-CoV-2 vaccines; mRNA booster; neutralizing antibodies.

MeSH terms

  • Antibodies, Neutralizing
  • Antibodies, Viral
  • COVID-19* / prevention & control
  • Humans
  • Patients
  • SARS-CoV-2* / genetics

Substances

  • Antibodies, Neutralizing
  • Antibodies, Viral

Supplementary concepts

  • SARS-CoV-2 variants

Grants and funding

This project has received funding from the University of Siena as part of “Piano di Sostegno alla Ricerca 2021 (PSR-2021)” program, “Curiosity-driven (F-CUR)”, research grant “COVI-VAC – Valutazione della risposta immunitaria umorale in seguito alla somministrazione di un vaccino a mRNA anti COVID-19 in una struttura penitenziaria di tipo sanitario.”